General Announcement::BM Intimation to Consider & Approve Unaudited Financial Results for 3rd Qtr & 9 Months 31.12.2018

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
04-Feb-2019 13:31:48
Status
New
Announcement Sub Title
BM Intimation to Consider & Approve Unaudited Financial Results for 3rd Qtr & 9 Months 31.12.2018
Announcement Reference
SG190204OTHR10VW
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary Compliance Officer
Effective Date and Time of the event
04/02/2019 10:55:00
Description (Please provide a detailed description of the event in the box below)
Pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday, February 14, 2019, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2018.

Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from January 1, 2019 to February 16, 2019 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2018.

Attachments

SGX_BM_Intimation_14022019.pdf
Total size =305K